Recent submissions
Now showing items 261-280 of 4698
-
Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
(MDPI, 2023-08-13)Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone ... -
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
(ELSEVIER SCIENCE INC, 2023-08-12)INTRODUCTION: This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib. METHODS: Patients with advanced ALK+ ... -
Reporting quality of CONSORT flow diagrams in published early phase dose-finding clinical trial reports: Improvement is needed.
(ELSEVIER SCIENCE INC, 2023-08-01)BACKGROUND: This project aims to: (1) assess the completeness of information in flow diagrams of published early phase dose-finding (EPDF) trials based on CONSORT recommendations, and if additional features on dose ... -
Medicines and Healthcare products Regulatory Agency’s “Consultation on proposals for legislative changes for clinical trials”: a response from the Trials Methodology Research Partnership Adaptive Designs Working Group, with a focus on data sharing
(Springer Science and Business Media LLC, 2023-10-05)<jats:title>Abstract</jats:title><jats:p>In the UK, the Medicines and Healthcare products Regulatory Agency consulted on proposals “to improve and strengthen the UK clinical trials legislation to help us make the UK the ... -
Radiological Biomarkers in MRI directed Rectal Cancer Radiotherapy Volume Delineation.
(MDPI, 2023-10-27)Our study evaluated whether an MRI reporting system highlighting areas of contiguous and discontinuous extramural venous invasion (EMVI) can improve the accuracy of gross tumour volume (GTV) delineation. Initially, 27 ... -
Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes.
(BMC, 2022-06-03)BACKGROUND: Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date ... -
TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.
(WILEY, 2022-07-31)OBJECTIVE: To assess feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle-invasive bladder cancer. PATIENTS AND METHODS: TUXEDO was a prospective, single-arm, open-label, phase ... -
Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
(BMC, 2022-09-05)BACKGROUND: Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide ... -
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
(BMJ PUBLISHING GROUP, 2023-01-01)BACKGROUND: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients ... -
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
(NATURE PORTFOLIO, 2023-01-19)Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of ... -
Mobile Health Solutions for Prostate Cancer Diagnostics-A Systematic Review.
(MDPI, 2023-07-28)Prostate cancer, the most common cause of cancer in men in the UK and one of the most common around the world to date, has no consensus on screening. Multiple large-scale trials from around the world have produced conflicting ... -
COmparing Urolift and Standard Transurethral resection of prostate Ahead of Radiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study.
(BMJ PUBLISHING GROUP, 2023-10-06)INTRODUCTION: Patients undergoing prostate radiotherapy with an enlarged prostate can have short-term and long-term urinary complications. Currently, transurethral resection of the prostate (TURP) is the mainstay surgical ... -
CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells.
(AMER ASSOC ADVANCEMENT SCIENCE, 2023-10-20)Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis because of its high propensity to metastasize and its immunosuppressive microenvironment. Using a panel of pancreatic cancer cell lines, three-dimensional ... -
Body Mindsets are Associated With Pain and Threat-Related Risk Factors for Pain in Survivors of Childhood Cancer.
(CHURCHILL LIVINGSTONE, 2023-08-06)Pain is a common consequence of childhood cancer. While most research has examined biomedical predictors of post-cancer pain, biopsychosocial conceptualisations such as the cancer threat interpretation (CTI) model hold ... -
Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response.
(WILEY, 2023-08-01)In recent years, the application of advanced analytics, especially artificial intelligence (AI), to digital H&E images, and other histological image types, has begun to radically change how histological images are used in ... -
Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-10-24)Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers of unmet need. In the advanced setting, and following failure of first-line anthracycline therapy, further line therapeutic options offer limited ... -
Exploring tumour evolution through single-cell sequencing
(Institute of Cancer Research (University Of London), 2023-10-24)Tumours are composed of heterogeneous populations of cells which, under the pressure of the host and external treatments, evolve across time and space. Recent advances in next-generation sequencing technologies have ... -
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.
(OXFORD UNIV PRESS, 2023-01-13)Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate ... -
A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR project.
(WILEY, 2024-04-01)Rhabdomyosarcoma is the commonest soft tissue sarcoma in children. Around one-third of children with rhabdomyosarcoma experience relapse or have refractory disease, which is associated with a poor prognosis. This systematic ... -
Applicability of Scoring Calyculin A-Induced Premature Chromosome Condensation Objects for Dose Assessment Including for Radiotherapy Patients.
(KARGER, 2023-10-19)As an extension to a previous study, a linear calibration curve covering doses from 0 to 10 Gy was constructed and evaluated in the present study using calyculin A-induced premature chromosome condensation (PCC) by scoring ...